Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a sell rating in a research note published on Thursday morning.

ARWR has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. B. Riley reiterated a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. Piper Sandler restated an “overweight” rating and issued a $62.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.33.

Arrowhead Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:ARWR opened at $20.84 on Thursday. The business has a fifty day simple moving average of $21.40 and a 200-day simple moving average of $23.99. Arrowhead Pharmaceuticals has a 52 week low of $17.05 and a 52 week high of $39.83. The company has a market cap of $2.59 billion, a P/E ratio of -4.90 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.80). The company’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.96) EPS. Sell-side analysts expect that Arrowhead Pharmaceuticals will post -4.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Arrowhead Pharmaceuticals by 16.2% in the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock valued at $354,756,000 after acquiring an additional 1,731,974 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 136.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,061,967 shares of the biotechnology company’s stock valued at $32,496,000 after purchasing an additional 613,067 shares during the period. Avoro Capital Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock valued at $231,022,000 after purchasing an additional 333,333 shares in the last quarter. American International Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 13.4% in the first quarter. American International Group Inc. now owns 220,217 shares of the biotechnology company’s stock worth $6,298,000 after purchasing an additional 26,009 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in Arrowhead Pharmaceuticals in the 1st quarter valued at about $3,663,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.